Tomosynthesis (3D) vs.
Digital Mammography (2D)
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST or study EA1151) is a randomized breast cancer screening study. The ECOG-ACRIN Cancer Research Group opened the trial on July 6, 2017, and is currently enrolling about 165,000 women who are planning to have regular mammograms.
TMIST is very important to the future of breast cancer screening because it will give us knowledge about how to move beyond our current “one size fits all” approach, where we screen most women the same way based on age-specific guidelines. The trial will help us move towards a more personalized approach that tailors mammography for each woman based on her own genetics and individual risk factors for developing breast cancer.
A mammogram can save your life by detecting breast cancer before any physical symptoms develop. When getting a mammogram, you might be asked to choose between two kinds of mammography: tomosynthesis (3D) or digital mammography (2D). While 3D mammography is newer, researchers do not know which type of mammography is better at detecting life-threatening breast cancers.
The NCI-funded Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is a study to compare these two types of mammograms. TMIST is also studying the biology of breast cancer to help personalize breast cancer screening in the future. Researchers plan to enroll 165,000 women ages 45 to 74 years old. Women can join the trial by contacting one of the participating mammography sites around the United States, Canada, and Argentina. Learn more about the trial at:
.png)
No hay comentarios:
Publicar un comentario